Filing of Registration Statement Proposed US IPO
November 08 2010 - 2:00AM
UK Regulatory
TIDMMEDG
RNS Number : 7654V
Medgenics Inc
08 November 2010
8 November 2010
Medgenics, Inc.
("Medgenics" or the "Company")
Medgenics Announces Filing of Registration Statement for Proposed Initial Public
Offering
of its Common Stock in the U.S.
Misgav, Israel and London, UK -8 November 2010 - Medgenics, Inc. (AIM: MEDG,
MEDU), today announced the filing of a registration statement on Form S-1 with
the U.S. Securities and Exchange Commission ("SEC") for the proposed initial
public offering of its common stock in the U.S.. The number of shares of common
stock to be offered and the price range for the offering have not yet been
determined. Roth Capital Partners, LLC and Maxim Group LLC are acting as
representatives of the underwriters in the offering.
A registration statement relating to the shares of common stock has been filed
with the SEC but has not yet become effective. The shares of common stock to be
sold in the offering may not be sold, nor may any offers to buy be accepted,
prior to the time the registration statement becomes effective. This release
shall not constitute an offer to sell or the solicitation of an offer to buy nor
shall there be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.
Sales of common stock under the registration statement cannot occur until it is
declared effective by the U.S. Securities and Exchange Commission, There can be
no assurance as to if and when the Securities and Exchange Commission will
declare the Company's registration statement effective. The registration
statement is available at the U.S. Securities and Exchange Commission's website
at www.sec.gov.
This offering of common stock will be made only by means of a prospectus. When
available, a written prospectus meeting the requirements of Section 10 of the
Securities Act of 1933, as amended, may be obtained from Roth Capital Partners,
LLC at 24 Corporate Plaza Dr., Newport Beach, CA 92660, attention: Equity
Capital Markets or 800-678-9147 or from Maxim Group LLC at 405 Lexington Avenue,
New York, New York 10174 or 800-724-0761.
For further information, contact:
+----------------------------------+--------------------------+
| Medgenics, Inc. | Phone: +972 4 902 8900 |
| Dr. Andrew L. Pearlman | |
| | |
+----------------------------------+--------------------------+
| De Facto Communications | Phone: +44 207 861 3838 |
| Mike Wort | |
| Anna Dunphy | |
| | |
+----------------------------------+--------------------------+
| Religare Capital Markets (Nomad) | Phone: +44 207 444 0800 |
| James Pinner | |
| Derek Crowhurst | |
| | |
+----------------------------------+--------------------------+
| SVS Securities plc (Joint | Phone: +44 207 638 5600 |
| Broker) | |
| Alex Mattey | |
| Ian Callaway | |
| | |
+----------------------------------+--------------------------+
| Nomura Code Securities (Joint | Phone: +44 207 776 1219 |
| Broker) | |
| Jonathan Senior | |
| | |
| | |
+----------------------------------+--------------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUWVNRRWAARRA
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024
